Curated News
By: NewsRamp Editorial Staff
June 24, 2026

Quantum BioPharma Advances Lucid-MS for Multiple Sclerosis

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS targets myelin directly, offering a novel advantage over existing MS therapies that only modulate immunity.
  • Lucid-MS is a neuroprotective compound that preserves myelin integrity, supported by over a decade of preclinical research and now entering phase 2 trials.
  • Lucid-MS aims to directly protect myelin in MS patients, potentially preserving neurological function and improving quality of life.
  • Quantum BioPharma is collaborating with Massachusetts General Hospital to develop a PET imaging technique to measure myelin integrity in MS patients.

Impact - Why it Matters

This news matters because it signals a potential shift in multiple sclerosis treatment from immune modulation to direct myelin protection. If Lucid-MS succeeds in clinical trials, it could offer a novel therapeutic option for the millions of MS patients worldwide who currently have limited alternatives. The collaboration with Massachusetts General Hospital on a PET imaging technique could also revolutionize how myelin repair is measured, accelerating development of remyelinating therapies across the field. Investors should note the progress as Quantum BioPharma moves closer to phase 2 trials, while patients may gain hope for a treatment that targets the root cause of disability in MS.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making strides in multiple sclerosis (MS) treatment with its lead drug candidate, Lucid-MS, a patented first-in-class compound designed to directly protect the myelin sheath. Unlike existing MS therapies that focus on modulating the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective agent aimed at preventing myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial after successful phase 1 safety studies and toxicology programs.

The editorial, disseminated via InvestorWire, highlights over a decade of preclinical research supporting Lucid-MS, including studies that demonstrated preservation of myelin integrity, reduced degradation, and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on a novel PET imaging technique to directly measure myelin integrity in MS patients, which could help evaluate remyelinating therapies. The report also notes recent developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscoring ongoing innovation in autoimmune and chronic inflammatory disease treatments.

Quantum BioPharma is dedicated to building a portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its subsidiary Lucid Psycheceuticals Inc., Quantum focuses on Lucid-MS, which has shown potential to prevent and reverse myelin degradation in preclinical models. The company also holds a stake in Unbuzzd Wellness Inc., which sells UNBUZZD(TM), an OTC product for alcohol effects, with royalty payments and rights for pharmaceutical use. For more details, visit the full press release at https://ibn.fm/6ylQf.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances Lucid-MS for Multiple Sclerosis

blockchain registration record for this content.